{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:05:29Z","timestamp":1790197529823,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The antilipidemic drug, probucol (PB), has demonstrated potential applications in Type 2 diabetes (T2D) through its protective effects on pancreatic \u03b2-cells. PB has poor solubility and bioavailability, and despite attempts to improve its oral delivery, none has shown dramatic improvements in absorption or antidiabetic effects. Preliminary data has shown potential benefits from bile acid co-encapsulation with PB. One bile acid has shown best potential improvement of PB oral delivery (ursodeoxycholic acid, UDCA). This study aimed to examine PB and UDCA microcapsules (with UDCA microcapsules serving as control) in terms of the microcapsules\u2019 morphology, biological effects <jats:italic>ex vivo<\/jats:italic>, and their hypoglycemic and antilipidemic and anti-inflammatory effects <jats:italic>in vivo<\/jats:italic>. PBUDCA and UDCA microcapsules were examined <jats:italic>in vitro<\/jats:italic> (formulation studies), <jats:italic>ex vivo<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. PBUDCA microcapsules exerted positive effects on \u03b2-cells viability at hyperglycemic state, and brought about hypoglycemic and anti-inflammatory effects on the prediabetic mice. In conclusion, PBUDCA co-encapsulation have showed beneficial therapeutic impact of dual antioxidant-bile acid effects in diabetes treatment.<\/jats:p>","DOI":"10.1038\/s41598-019-53999-1","type":"journal-article","created":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T11:02:26Z","timestamp":1578567746000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-2067","authenticated-orcid":false,"given":"Armin","family":"Mooranian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9867-8896","authenticated-orcid":false,"given":"Susbin","family":"Raj Wagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bozica","family":"Kovacevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6359-3382","authenticated-orcid":false,"given":"Ryu","family":"Takechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Mamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momir","family":"Mikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Golocorbin-Kon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Stojanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Al-Sallami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Al-Salami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,9]]},"reference":[{"issue":"12","key":"53999_CR1","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1101\/gad.1550907","volume":"21","author":"M Qatanani","year":"2007","unstructured":"Qatanani, M. & Lazar, M. A. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev 21(12), 1443\u201355 (2007).","journal-title":"Genes Dev"},{"issue":"2","key":"53999_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/MED.0b013e3283514e13","volume":"19","author":"OT Hardy","year":"2012","unstructured":"Hardy, O. T., Czech, M. P. & Corvera, S. What causes the insulin resistance underlying obesity?. Curr Opin Endocrinol Diabetes Obes 19(2), 81\u20137 (2012).","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"53999_CR3","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif Cells Nanomed Biotechnol, p. 1\u201312, (2015).","DOI":"10.3109\/21691401.2015.1069299"},{"issue":"2","key":"53999_CR4","first-page":"49","volume":"1","author":"R Negrulj","year":"2013","unstructured":"Negrulj, R., Mooranian, A. & Al-Salami, H. Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System. Journal of Endocrinology and Diabetes Mellitus 1(2), 49\u201359 (2013).","journal-title":"Journal of Endocrinology and Diabetes Mellitus"},{"issue":"2","key":"53999_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12668-016-0198-9","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian, A., Negrulj, R. & Al-Salami, H. Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine \u03b2-cell Survival and the Inflammatory Response. BioNanoScience 6(2), 103\u2013109 (2016).","journal-title":"BioNanoScience"},{"issue":"8","key":"53999_CR6","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3109\/10717544.2015.1110846","volume":"23","author":"S Mathavan","year":"2016","unstructured":"Mathavan, S. et al. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes. Drug Deliv 23(8), 2869\u20132880 (2016).","journal-title":"Drug Deliv"},{"issue":"5","key":"53999_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/ane.12474","volume":"133","author":"T Duksal","year":"2016","unstructured":"Duksal, T. et al. Role of inflammation in sensory neuropathy in prediabetes or diabetes. Acta Neurol Scand 133(5), 384\u201390. (2016).","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"53999_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00125-014-3482-7","volume":"58","author":"JA Ehses","year":"2015","unstructured":"Ehses, J. A. & Donath, M. Y. Targeting 12-lipoxygenase as a novel strategy to combat the effects of inflammation on beta cells in diabetes. Diabetologia 58(3), 425\u20138 (2015).","journal-title":"Diabetologia"},{"issue":"10","key":"53999_CR9","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.2337\/db11-0425","volume":"60","author":"F Karpe","year":"2011","unstructured":"Karpe, F., Dickmann, J. R. & Frayn, K. N. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 60(10), 2441\u20139 (2011).","journal-title":"Diabetes"},{"key":"53999_CR10","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. Advanced bile acid-based multi-compartmental microencapsulated pancreatic beta-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment. Artif Cells Nanomed Biotechnol, p. 1\u20138, (2014).","DOI":"10.3109\/21691401.2014.971806"},{"issue":"6","key":"53999_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3109\/10837450.2014.915570","volume":"20","author":"A Mooranian","year":"2015","unstructured":"Mooranian, A. et al. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharm Dev Technol 20(6), 702\u20139 (2015).","journal-title":"Pharm Dev Technol"},{"issue":"2","key":"53999_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12247-016-9248-7","volume":"11","author":"A Mooranian","year":"2016","unstructured":"Mooranian, A., Negrulj, R. & Al-Salami, H. Alginate-deoxycholic Acid Interaction and Its Impact on Pancreatic \u0392-Cells and Insulin Secretion and Potential Treatment of Type 1 Diabetes. Journal of Pharmaceutical Innovation 11(2), 156\u2013161 (2016).","journal-title":"Journal of Pharmaceutical Innovation"},{"key":"53999_CR13","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. Biological assessments of encapsulated pancreatic \u03b2-cells: Their potential transplantation in diabetes. Cellular and Molecular Bioengineering, 2016 (in press).","DOI":"10.1007\/s12195-016-0441-z"},{"key":"53999_CR14","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study. Drug Delivery and Translational Research, p. 1\u201312 (2015).","DOI":"10.1007\/s13346-015-0248-9"},{"issue":"14","key":"53999_CR15","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3748\/wjg.15.1677","volume":"15","author":"MJ Perez","year":"2009","unstructured":"Perez, M. J. & Briz, O. Bile-acid-induced cell injury and protection. World J Gastroenterol 15(14), 1677\u201389 (2009).","journal-title":"World J Gastroenterol"},{"issue":"2","key":"53999_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.intimp.2012.11.017","volume":"15","author":"P Martinez-Moya","year":"2013","unstructured":"Martinez-Moya, P. et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol 15(2), 372\u201380 (2013).","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"53999_CR17","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1194\/jlr.R900011-JLR200","volume":"50","author":"JD Amaral","year":"2009","unstructured":"Amaral, J. D. et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 50(9), 1721\u201334 (2009).","journal-title":"J Lipid Res"},{"issue":"sup3","key":"53999_CR18","doi-asserted-by":"publisher","first-page":"S748","DOI":"10.1080\/21691401.2018.1511572","volume":"46","author":"A Mooranian","year":"2018","unstructured":"Mooranian, A. et al. Pharmacological effects of nanoencapsulation of human-based dosing of probucol on ratio of secondary to primary bile acids in gut, during induction and progression of type 1 diabetes. Artif Cells Nanomed Biotechnol 46(sup3), S748\u2013S754 (2018).","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"11","key":"53999_CR19","doi-asserted-by":"publisher","first-page":"811","DOI":"10.4155\/tde-2018-0036","volume":"9","author":"A Mooranian","year":"2018","unstructured":"Mooranian, A. et al. Eudragit((R))-based microcapsules of probucol with a gut-bacterial processed secondary bile acid. Ther Deliv 9(11), 811\u2013821 (2018).","journal-title":"Ther Deliv"},{"key":"53999_CR20","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. The biological effects of the hypolipidaemic drug probucol incorporated into bile acid-microcapsules and fed daily for 4-weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Delivery and Translational Research, 2018 In press.","DOI":"10.1007\/s13346-017-0473-5"},{"issue":"7","key":"53999_CR21","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.metabol.2011.10.023","volume":"61","author":"T Tsuchida","year":"2012","unstructured":"Tsuchida, T. et al. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism 61(7), 944\u201353 (2012).","journal-title":"Metabolism"},{"issue":"1","key":"53999_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/2193-1801-2-20","volume":"2","author":"M Murakami","year":"2013","unstructured":"Murakami, M. et al. Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects. Springerplus 2(1), 20 (2013).","journal-title":"Springerplus"},{"issue":"1","key":"53999_CR23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000324146","volume":"29","author":"HU Marschall","year":"2011","unstructured":"Marschall, H. U. et al. Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. Dig Dis 29(1), 117\u20138 (2011).","journal-title":"Dig Dis"},{"issue":"5","key":"53999_CR24","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1158\/1055-9965.861.13.5","volume":"13","author":"LM Hess","year":"2004","unstructured":"Hess, L. M. et al. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid. Cancer Epidemiol Biomarkers Prev 13(5), 861\u20137 (2004).","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"53999_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s13346-015-0268-5","volume":"6","author":"A Mooranian","year":"2016","unstructured":"Mooranian, A., Negrulj, R. & Al-Salami, H. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable beta-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies. Drug Deliv Transl Res 6(1), 17\u201323 (2016).","journal-title":"Drug Deliv Transl Res"},{"issue":"5","key":"53999_CR26","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1007\/s11095-016-1863-y","volume":"33","author":"A Mooranian","year":"2016","unstructured":"Mooranian, A., Negrulj, R. & Al-Salami, H. The Influence of Stabilized Deconjugated Ursodeoxycholic Acid on Polymer-Hydrogel System of Transplantable NIT-1 Cells. Pharm Res 33(5), 1182\u201390 (2016).","journal-title":"Pharm Res"},{"key":"53999_CR27","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study. J Microencapsul: p. 1\u20139 (2015).","DOI":"10.3109\/02652048.2015.1065922"},{"key":"53999_CR28","unstructured":"Negrulj, R. et al. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes. Artif Cells Nanomed Biotechnol, p. 1\u20138 (2015)."},{"key":"53999_CR29","first-page":"1673","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian, A. et al. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer. Drug Des Devel Ther 8, 1673\u201383 (2014).","journal-title":"Drug Des Devel Ther"},{"key":"53999_CR30","unstructured":"Mooranian, A. et al. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment. J Microencapsul, p. 1\u20136 (2014)."},{"key":"53999_CR31","first-page":"1221","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian, A. et al. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol. Drug Des Devel Ther 8, 1221\u201330 (2014).","journal-title":"Drug Des Devel Ther"},{"key":"53999_CR32","first-page":"1003","volume":"8","author":"A Mooranian","year":"2014","unstructured":"Mooranian, A. et al. Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: a characterization study. Drug design, development and therapy 8, 1003 (2014).","journal-title":"Drug design, development and therapy"},{"key":"53999_CR33","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. Probucol Release from Novel Multicompartmental Microcapsules for the Oral Targeted Delivery in Type 2 Diabetes. AAPS PharmSciTech (2014).","DOI":"10.1208\/s12249-014-0205-9"},{"key":"53999_CR34","doi-asserted-by":"crossref","unstructured":"Mooranian, A. et al. Stability and Release Kinetics of an Advanced Gliclazide-Cholic Acid Formulation: The Use of Artificial-Cell Microencapsulation in Slow Release Targeted Oral Delivery of Antidiabetics. Journal of Pharmaceutical Innovation, p. 1\u20138 (2014).","DOI":"10.1007\/s12247-014-9182-5"},{"issue":"1","key":"53999_CR35","first-page":"28","volume":"125","author":"H Al-Salami","year":"2017","unstructured":"Al-Salami, H. et al. Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance. Exp Clin Endocrinol Diabetes 125(1), 28\u201332 (2017).","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"2","key":"53999_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/02652048409038515","volume":"1","author":"GR Hunt","year":"1984","unstructured":"Hunt, G. R. & Jones, I. C. Application of 1H-n.m.r. to the design of liposomes for oral use. Synergistic activity of bile salts and pancreatic phospholipase A2 in the induced permeability of small unilamellar phospholipid vesicles. J Microencapsul 1(2), 113\u201322 (1984).","journal-title":"J Microencapsul"},{"issue":"211","key":"53999_CR37","doi-asserted-by":"publisher","first-page":"211ra156","DOI":"10.1126\/scitranslmed.3006534","volume":"5","author":"F Engin","year":"2013","unstructured":"Engin, F. et al. Restoration of the unfolded protein response in pancreatic beta cells protects mice against type 1 diabetes. Sci Transl Med 5(211), 211ra156 (2013).","journal-title":"Sci Transl Med"},{"issue":"7","key":"53999_CR38","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1053\/gast.2002.33617","volume":"122","author":"JY Kim","year":"2002","unstructured":"Kim, J. Y. et al. Transporter-mediated bile acid uptake causes Ca2+-dependent cell death in rat pancreatic acinar cells. Gastroenterology 122(7), 1941\u201353 (2002).","journal-title":"Gastroenterology"},{"issue":"3","key":"53999_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbamcr.2006.04.014","volume":"1773","author":"A Geier","year":"2007","unstructured":"Geier, A. et al. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 1773(3), 283\u2013308 (2007).","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"53999_CR40","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1161\/01.ATV.19.5.1325","volume":"19","author":"F Rinninger","year":"1999","unstructured":"Rinninger, F. et al. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol 19(5), 1325\u201332 (1999).","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"53999_CR41","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1021\/mp500388m","volume":"12","author":"Q Ma","year":"2015","unstructured":"Ma, Q. et al. Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes. Mol Pharm 12(3), 665\u201374 (2015).","journal-title":"Mol Pharm"},{"issue":"1","key":"53999_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF03191383","volume":"34","author":"H Al-Salami","year":"2009","unstructured":"Al-Salami, H. et al. Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats. European Journal of Drug Metabolism and Pharmacokinetics 34(1), 43\u201350 (2009).","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"issue":"4","key":"53999_CR43","doi-asserted-by":"publisher","first-page":"383 e1","DOI":"10.1016\/j.ajog.2010.01.035","volume":"202","author":"SJ Hemauer","year":"2010","unstructured":"Hemauer, S. J. et al. Role of human placental apical membrane transporters in the efflux of glyburide, rosiglitazone, and metformin. Am J Obstet Gynecol 202(4), 383 e1\u20137 (2010).","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"53999_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3109\/03602532.2012.748793","volume":"45","author":"JL Staudinger","year":"2013","unstructured":"Staudinger, J. L. et al. Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. Drug Metab Rev 45(1), 48\u201359 (2013).","journal-title":"Drug Metab Rev"},{"issue":"5","key":"53999_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1124\/mol.60.5.934","volume":"60","author":"Y Cui","year":"2001","unstructured":"Cui, Y., Konig, J. & Keppler, D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Mol Pharmacol 60(5), 934\u201343 (2001).","journal-title":"Mol Pharmacol"},{"issue":"9","key":"53999_CR46","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1124\/dmd.105.008748","volume":"34","author":"S Mita","year":"2006","unstructured":"Mita, S. et al. Inhibition of bile acid transport across Na+\/Taurocholate co-transporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11) - expressing LLC-PK1 cells by cholestasis- inducing drugs. Drug Metab Dispos 34(9), 1575\u20131581 (2006).","journal-title":"Drug Metab Dispos"},{"issue":"16","key":"53999_CR47","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.1016\/j.bmc.2013.04.020","volume":"21","author":"DJ Sherman","year":"2013","unstructured":"Sherman, D. J. et al. Validation of inhibitors of an ABC transporter required to transport lipopolysaccharide to the cell surface in Escherichia coli. Bioorg Med Chem 21(16), 4846\u201351 (2013).","journal-title":"Bioorg Med Chem"},{"issue":"1\u20133","key":"53999_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.cbi.2012.04.008","volume":"198","author":"C Della Torre","year":"2012","unstructured":"Della Torre, C. et al. Interaction of ABC transport proteins with toxic metals at the level of gene and transport activity in the PLHC-1 fish cell line. Chem Biol Interact 198(1\u20133), 9\u201317 (2012).","journal-title":"Chem Biol Interact"},{"issue":"4","key":"53999_CR49","first-page":"532","volume":"60","author":"H Al-Salami","year":"2008","unstructured":"Al-Salami, H. et al. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Pharmacological Reports 60(4), 532\u2013541 (2008).","journal-title":"Pharmacological Reports"},{"issue":"2","key":"53999_CR50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1358\/mf.2008.30.2.1159652","volume":"30","author":"H Al-Salami","year":"2008","unstructured":"Al-Salami, H. et al. Influence of the semisynthetic bile acid MKC on the ileal permeation of gliclazide in vitro in healthy and diabetic rats treated with probiotics. Methods Find Exp Clin Pharmacol 30(2), 107\u201313 (2008).","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"11\u201312","key":"53999_CR51","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.placenta.2005.11.012","volume":"27","author":"C Gedeon","year":"2006","unstructured":"Gedeon, C. et al. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure. Placenta 27(11\u201312), 1096\u2013102 (2006).","journal-title":"Placenta"},{"issue":"6","key":"53999_CR52","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1210\/endo.136.6.7750472","volume":"136","author":"E Tsiani","year":"1995","unstructured":"Tsiani, E. et al. Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136(6), 2505\u201312 (1995).","journal-title":"Endocrinology"},{"key":"53999_CR53","doi-asserted-by":"crossref","unstructured":"Davignon, J. Probucol, in Principles and Treatment of Lipoprotein Disorders., Springer. p. 429\u2013469 (1994).","DOI":"10.1007\/978-3-642-78426-2_15"},{"issue":"6","key":"53999_CR54","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2165\/00003495-198937060-00002","volume":"37","author":"MT Buckley","year":"1989","unstructured":"Buckley, M. T. et al. Probucol. Drugs 37(6), 761\u2013800 (1989).","journal-title":"Drugs"},{"issue":"3","key":"53999_CR55","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1021\/mp9000487","volume":"6","author":"T Fukami","year":"2009","unstructured":"Fukami, T. et al. Nanoparticle processing in the solid state dramatically increases the cell membrane permeation of a cholesterol-lowering drug, probucol. Mol Pharm 6(3), 1029\u201335 (2009).","journal-title":"Mol Pharm"},{"issue":"9","key":"53999_CR56","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1007\/s11095-014-1321-7","volume":"31","author":"Z Zhang","year":"2014","unstructured":"Zhang, Z. et al. Directed self-assembled nanoparticles of probucol improve oral delivery: fabrication, performance and correlation. Pharm Res 31(9), 2266\u201375 (2014).","journal-title":"Pharm Res"},{"issue":"4","key":"53999_CR57","first-page":"530","volume":"9","author":"A Mooranian","year":"2016","unstructured":"Mooranian, A. et al. Biological Assessments of Encapsulated Pancreatic \u03b2-Cells: Their Potential Transplantation in Diabetes. Cellular and Molecular. Bioengineering 9(4), 530\u2013537 (2016).","journal-title":"Bioengineering"},{"issue":"2","key":"53999_CR58","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/btpr.2223","volume":"32","author":"A Mooranian","year":"2016","unstructured":"Mooranian, A. et al. Designing anti-diabetic beta-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis. Biotechnol Prog 32(2), 501\u20139 (2016).","journal-title":"Biotechnol Prog"},{"issue":"12","key":"53999_CR59","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1111\/j.1751-7176.2010.00389.x","volume":"12","author":"A Perez","year":"2010","unstructured":"Perez, A. et al. Effects of pioglitazone and metformin fixed-dose combination therapy on cardiovascular risk markers of inflammation and lipid profile compared with pioglitazone and metformin monotherapy in patients with type 2 diabetes. J Clin Hypertens (Greenwich) 12(12), 973\u201382 (2010).","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"1","key":"53999_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2009.08.030","volume":"290","author":"MK Baek","year":"2010","unstructured":"Baek, M. K. et al. Lithocholic acid upregulates uPAR and cell invasiveness via MAPK and AP-1 signaling in colon cancer cells. Cancer Lett 290(1), 123\u20138 (2010).","journal-title":"Cancer Lett"},{"issue":"2","key":"53999_CR61","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/bj2360345","volume":"236","author":"SG Barnwell","year":"1986","unstructured":"Barnwell, S. G., Yousef, I. M. & Tuchweber, B. The effect of colchicine on the development of lithocholic acid-induced cholestasis. A study of the role of microtubules in intracellular cholesterol transport. Biochem J 236(2), 345\u201350 (1986).","journal-title":"Biochem J"},{"issue":"1","key":"53999_CR62","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1748-1716.1954.tb01071.x","volume":"30","author":"S Bergstrom","year":"1953","unstructured":"Bergstrom, S., Sjovall, J. & Voltz, J. Metabolism of lithocholic acid in the rat. IX. Bile acids and steroids. Acta Physiol Scand 30(1), 22\u201332 (1953).","journal-title":"Acta Physiol Scand"},{"issue":"7","key":"53999_CR63","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3109\/21691401.2015.1069299","volume":"44","author":"A Mooranian","year":"2016","unstructured":"Mooranian, A. et al. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic beta-cell line. Artif Cells Nanomed Biotechnol 44(7), 1642\u201353 (2016).","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"11","key":"53999_CR64","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1210\/jc.2017-01091","volume":"102","author":"A Bronden","year":"2017","unstructured":"Bronden, A. et al. Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. J Clin Endocrinol Metab 102(11), 4153\u20134162 (2017).","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"53999_CR65","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/dom.12656","volume":"18","author":"DJ Nunez","year":"2016","unstructured":"Nunez, D. J. et al. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. Diabetes Obes Metab 18(7), 654\u201362 (2016).","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"53999_CR66","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/(SICI)1096-9136(199808)15:8<651::AID-DIA628>3.0.CO;2-A","volume":"15","author":"JH Scarpello","year":"1998","unstructured":"Scarpello, J. H., Hodgson, E. & Howlett, H. C. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabet Med 15(8), 651\u20136 (1998).","journal-title":"Diabet Med"},{"issue":"3","key":"53999_CR67","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1172\/JCI68815","volume":"124","author":"F Lien","year":"2014","unstructured":"Lien, F. et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest 124(3), 1037\u201351 (2014).","journal-title":"J Clin Invest"},{"issue":"10","key":"53999_CR68","doi-asserted-by":"publisher","first-page":"751","DOI":"10.2165\/00003088-200241100-00005","volume":"41","author":"MS Roberts","year":"2002","unstructured":"Roberts, M. S. et al. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41(10), 751\u201390 (2002).","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"53999_CR69","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/archinte.1972.03650040078008","volume":"130","author":"DM Small","year":"1972","unstructured":"Small, D. M., Dowling, R. H. & Redinger, R. N. The enterohepatic circulation of bile salts. Arch Intern Med 130(4), 552\u201373 (1972).","journal-title":"Arch Intern Med"},{"key":"53999_CR70","doi-asserted-by":"crossref","unstructured":"Mooranian, A., et al., An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations. Pharmaceutical Development and Technology, 20(6), 702\u20139 (2015).","DOI":"10.3109\/10837450.2014.915570"},{"issue":"22","key":"53999_CR71","doi-asserted-by":"publisher","first-page":"8896","DOI":"10.1021\/jf0715166","volume":"55","author":"KL Wolfe","year":"2007","unstructured":"Wolfe, K. L. & Liu, R. H. Cellular antioxidant activity (CAA) assay for assessing antioxidants, foods, and dietary supplements. J Agric Food Chem 55(22), 8896\u2013907 (2007).","journal-title":"J Agric Food Chem"},{"issue":"2","key":"53999_CR72","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1358\/mf.2008.30.2.1159652","volume":"30","author":"H Al-Salami","year":"2008","unstructured":"Al-Salami, H. et al. Influence of the semisynthetic bile acid (MKC) on the ileal permeation of gliclazide in healthy and diabetic rats. Methods Find Exp Clin Pharmacol 30(2), 107\u2013113 (2008).","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"2","key":"53999_CR73","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s13318-011-0060-y","volume":"37","author":"H Al-Salami","year":"2012","unstructured":"Al-Salami, H. et al. Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats. Eur J Drug Metab Pharmacokinet 37(2), 99\u2013108 (2012).","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"1","key":"53999_CR74","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1753-5174.2008.00006.x","volume":"1","author":"H Al-Salami","year":"2008","unstructured":"Al-Salami, H. et al. Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats. Arch Drug Inf 1(1), 35\u201341 (2008).","journal-title":"Arch Drug Inf"},{"issue":"1","key":"53999_CR75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11745-011-3595-4","volume":"47","author":"MM Pallebage-Gamarallage","year":"2012","unstructured":"Pallebage-Gamarallage, M. M. et al. Probucol suppresses enterocytic accumulation of amyloid-\u03b2 induced by saturated fat and cholesterol feeding. Lipids 47(1), 27\u201334 (2012).","journal-title":"Lipids"},{"issue":"1","key":"53999_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-11-117","volume":"11","author":"M Pallebage-Gamarallage","year":"2012","unstructured":"Pallebage-Gamarallage, M. et al. Restoration of dietary-fat induced blood\u2013brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids in health and disease 11(1), 1 (2012).","journal-title":"Lipids in health and disease"},{"issue":"6","key":"53999_CR77","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s11095-017-2138-y","volume":"34","author":"A Mooranian","year":"2017","unstructured":"Mooranian, A. et al. Innovative Microcapsules for Pancreatic beta-Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines Analysis. Pharm Res 34(6), 1217\u20131223 (2017).","journal-title":"Pharm Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53999-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53999-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T05:22:06Z","timestamp":1670304126000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53999-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,9]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["53999"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53999-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,9]]},"assertion":[{"value":"14 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}